Cookies
We use essential cookies to run the site. Analytics cookies are optional and help us improve World Wide. Learn more.
Clinical Psychopharmacology Research Group, Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK.
Showing your local timezone
Schedule
Friday, July 1, 2022
4:30 PM Europe/Zurich
Domain
NeuroscienceHost
NeuroLeman Network
Duration
70 minutes
Development of new medications for mental health conditions is a pressing need given the high proportion of people not responding to available treatments. We hope that presenting ebselen to a wider audience will inspire further studies on this promising agent with a benign side-effects profile. Laboratory research, animal research and human studies suggest that ebselen shares many features with the mood stabilising drug lithium, creating a promise of a drug that would have a similar clinical effect but without lithium’s troublesome side-effect profile and toxicity. Both drugs have a common biological target, inositol monophosphatase, whose inhibition is thought key to lithium’s therapeutic effect. Both drugs have neuroprotective action and reduce oxidative stress. In animal studies, ebselen affected neurotransmitters involved in the development of mental health symptoms, and in particular, produced effects of serotonin function very similar to lithium. Both ebselen and lithium share behavioural effects: antidepressant-like effects in rodent models of depression and decrease in behavioural impulsivity, a property associated with lithium's anti-suicidal action. Human neuropsychological studies support an antidepressant profile for ebselen based on its positive impact on emotional processing and reward seeking. Our group currently is exploring ebselen’s effects in patients with mood disorders. A completed ‘add-on’ clinical trial in mania showed ebselen’s superiority over placebo after three weeks of treatment. Our ongoing experimental research explores ebselen’s antidepressant profile in patients with treatment resistant depression. If successful, this will lead to a clinical trial of ebselen as an antidepressant augmentation agent, similar to lithium.
Beata R. Godlewska
Clinical Psychopharmacology Research Group, Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK.
neuro
Nervous system function relies on the polarized architecture of neurons, established by directional transport of pre- and postsynaptic cargoes. While delivery of postsynaptic components depends on the
neuro
A combinatorial neural code for long-term motor memory
neuro
The postdoctoral researcher will work on an interdisciplinary project at the intersection of deep learning and comparative politics. The candidate will work in the Human-Centered Machine Learning (HuM
We are looking for highly motivated researchers to join our group in interdisciplinary projects that focus on the development of computational models to understand how linguistic information is repres
The CSNG Lab at the Faculty of Mathematics and Physics at the Charles University is seeking a highly motivated Postdoctoral Researcher to join our team to work on a digital twin model of the visual sy
PROJECT SUMMARY / ABSTRACT Cluster headache (CH), which affects about 1 in 1,000 people, is a severe and debilitating primary headache disorder characterized by repeated attacks occurring in clusters